去纤苷是医保药物吗？

(Defibrotide) is indicated for the treatment of hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal and pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients. Hepatic veno-occlusive disease is the disease with the highest morbidity and mortality caused by hematopoietic stem cell transplantation. Apart from symptomatic and supportive treatment, there are no effective prevention and treatment methods. An open-label randomized phase III trial led by the University of Regensburg in Germany showed that defibrotide can reduce the risk of this disease.  

Defibrotide is approved for marketing in the following countries: Defibrotide is available/approved in the United States and Europe; Defibrotide in Southeast Asia - Cambodia, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, Hong Kong; Defibrotide in the United Arab Emirates - Iraq, Iran, Saudi Arabia, Jordan; Defibrotide Defibrotide is in North America and Mexico; Defibrotide is in South America - Argentina, Brazil, Chile, Colombia, Peru, Venezuela; Defibrotide is in Europe - Romania, Switzerland, Georgia, Turkey, Italy, the United Kingdom, Ukraine, Azerbaijan, Latvia, Poland, Slovakia; Defibrotide is in Europe CIS - Armenia in Russia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia; Defibrotide in African countries - Algeria, Mauritius, Uganda, Zimbabwe; Defibrotide in Australia and New Zealand. 

It can be seen that Defibrotide has not been approved for marketing in my country, let alone a medical insurance drug. Prior to this, domestic patients could obtain overseas cost-effective versions of Defibrotide through domestic professional overseas medical service agencies, such as Medical Companion Travel.